This job is no longer available
There are still lots of open positions. Let's find the one that's right for you.
The Global Program Head (GPH) for Oncology at Regeneron Pharmaceuticals is a pivotal role that drives the creation of an integrated program strategy by engaging with and incorporating insights from all relevant key stakeholders. The GPH is responsible for ensuring that Executive Management is equipped with the necessary information through discussions and presentations to authorize final program strategy decisions. This position co-leads the asset strategic team and, alongside their clinical co-leader, oversees program execution and management. The GPH will be instrumental in advancing several of Regeneron's oncology antibody programs from lead selection through to the Biologics License Application (BLA). This role has a significant impact across the organization, interacting with various departments including research, non-clinical, clinical, medical safety, development, program management, regulatory, commercial, and industrial operations (manufacturing) to devise and execute development strategies for antibody programs. A typical day for the Global Program Head may involve leveraging deep knowledge of the oncology therapeutic area to facilitate interactions and contributions across the entire spectrum of drug discovery and late-stage development. The GPH will identify and align key stakeholders across Regeneron and its partners, ensuring their engagement in program development strategies. The role requires providing sound strategic guidance for therapeutic area development strategies that encompass research, clinical, regulatory, supply chain considerations, and commercial needs. The GPH must ensure that scientific rigor and innovation are integral to the program development strategies, driving a broader cross-functional perspective that includes scientific rationale, operational feasibility, budgeting, timelines, and an understanding of the competitive and commercial landscape. Additionally, the GPH will adeptly translate development program strategies and recommendations between teams and senior management, representing Regeneron at joint development committees.
